The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Nurofen Plus Tablets Ibuprofen 200mg Codeine Phosphate Hemihydrate 12.8mg

Reckitt Benckiser Ireland LtdPA0979/034/001

Main Information

Trade NameNurofen Plus Tablets Ibuprofen 200mg Codeine Phosphate Hemihydrate 12.8mg
Active SubstancesIbuprofen
Codeine phosphate hemihydrate
Dosage FormFilm-coated tablet
Licence HolderReckitt Benckiser Ireland Ltd
Licence NumberPA0979/034/001

Group Information

ATC CodeN02AJ Opioids in combination with non-opioid analgesics
N02AJ08 codeine and ibuprofen


License statusAuthorised
Licence Issued21/03/1997
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceProduct not subject to medical prescription, supply through pharmacies only and promotion to the healthcare professionals only subject to the following restrictions: For ibuprofen: maximum strength 200 mg, maximum dose: 400 mg, maximum daily dose 1200 mg, limited indications. For use in adults and children not under 12 years. For codeine: maximum dose equivalent of 20 mg. Packs containing more than 24 tablets are prescription only.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back